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Summary: To estimate the change in AIDS incubation time during three periods
characterized by different availability of antiretroviral treatments, data from the French
Hospital Database on HIV of 4702 HIV-1–positive subjects with a documented date of
infection were analyzed. Times from seroconversion to AIDS were compared in three
periods: period 1 from January 1992 to June 1995 (monotherapy); period 2 from July
1995 to June 1996 (dual therapy); and period 3 from July 1996 to June 1999 (triple
therapy). Nonparametric survival analyses were performed to account for staggered
entries in the database and during each period. From periods 1 to 3, antiretroviral
treatments were initiated earlier after infection, more subjects were treated, and the
nature of regimens changed (25.6% of subjects were treated with monotherapy in
period 1, 34.6% were treated with dual therapy in period 2, and 53.4% were treated
with triple therapy in period 3). Compared with period 1, the relative hazard (RH) of
AIDS was 0.31 in period 3 (95% confidence interval [CI]: 0.24–0.39). When com-
paring period 3 with period 2, the RH of AIDS was 0.36 (CI: 0.29–0.45). Assuming
a log normal distribution, the median time to AIDS was estimated as 8.0 years in
period 1 (CI: 6.0–10.6), 9.8 years in period 2 (CI: 8.5, 11.2), and 20.0 years in period
3 (CI: 17.1–23.3). This lengthening in time to AIDS from 1992 to 1999 was particu-
larly marked in the period after the introduction of triple therapy, including protease
inhibitors. Key Words: AIDS—Cohort study—Disease progression—HIV—Highly
active antiretroviral therapy—Incubation duration.
The quantitative estimate of time to AIDS in observa-
tional studies is an important parameter in public health
to assess the impact of the HIV epidemic and its control.
It provides a measure of the population effectiveness of
therapies (1) in contrast to clinical trials, which measure
the therapeutic efficacy at an individual level. Impor-
tantly, it can also contribute to an estimation of the size
of the HIV-infected population, using back-calculation
approach accounting for treatment effect and guiding
public health interventions (2).
Changes in treatments (antiretroviral and prophylac-
tic) together with global health care, HIV strain viru-
lence, AIDS events classification, and diagnosis ability
are factors capable of influencing the time between HIV
infection and the development of AIDS (3,4). In a popu-
lation, the clinical impact of the spread of a new therapy
might be assessed by comparing clinical progression
rates across different calendar periods. Using this ap-
proach, previous studies on HIV seroconverters focused
on progression to death only (5,6), whereas Detels et al.
(7) also considered the progression to AIDS.
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81The French Hospital Database on HIV, whose data are
provided by HIV-specialized hospitals, represents an op-
portunity to evaluate the change in time to AIDS. The
goal of our study was to estimate the time to AIDS
during three periods of follow-up characterized by dif-
ferent availability of antiretroviral treatments.
MATERIALS AND METHODS
Database
The French Hospital Database on HIV is a clinical epidemiologic
network started in 1989 with 29 Centers d’Information et de Soins de
l’Immunodéficience Humaine especially involved in the medical care
of HIV-infected persons at 68 French university hospitals (8). National
coverage was achieved in 1992. In brief, patients with a documented
HIV infection who have signed an informed consent form are enrolled
during their first hospital visit. Trained research assistants collect data
on a standardized form at inclusion, at each visit or hospital admission
for an HIV-related clinical diagnosis, at the time of a new treatment
prescription, or at least every 6 months. Data are computerized locally
using the French Ministry of Health software, DM12. Sex, transmission
group, date of birth, and date of first HIV-positive test are systemati-
cally collected at inclusion. When available, date of last negative HIV
test, date of contamination, and date of primary HIV infection are also
collected. Data collected during each follow-up visit include biologic
markers, clinical HIV-related manifestations, nature of treatments pre-
scribed, and date of death. At the time of the study, the last update was
in December 1999.
Date of HIV-1 Infection
Eligible patients for the current study were those whose date of
HIV-1 infection could be documented on the basis of the date of a
patient’s last negative HIV test, date of primary infection, or date of
contamination. Primary infection, defined by the presence of typical
signs and symptoms followed by HIV seroconversion, was ascertained
by a physician. The date of contamination was the date of the risk
exposure assessed by a physician according to a patient’s history. The
date of HIV-1 infection was estimated as the midpoint between the date
of the last negative and first positive HIV tests (test interval) within an
interval of 24 months when the dates of primary infection or contami-
nation were not documented. Otherwise, we assumed the date of in-
fection to be the date of primary infection, if available, or as the date
of contamination.
Inclusion Criteria
Inclusion was restricted to the HIV-1–infected adults whose date of
infection was documented after 1985, who were AIDS-free as of De-
cember 1991, and who had at least one follow-up visit, except in the
case of a first AIDS-defining event diagnosed at the first visit. Subjects
involved in a double-blind antiretroviral trial during their follow-up
period (n  246), diagnosed with AIDS before database entry (n 
372), or with a follow-up interval of less than 6 months (n  99) were
excluded.
Estimation of Incubation Time
Patients were followed until AIDS, death, last follow-up, or June
1999, whichever occurred first. AIDS was defined according to the
Centers for Disease Control and Prevention’s 1993 clinical classifica-
tion. Three calendar periods were defined according to the availability
of antiretroviral regimens in France: January 1992 to June 1995 (period
1: mainly nucleoside reverse transcriptase inhibitor [NRTI] mono-
therapy), July 1995 to June 1996 (period 2: mainly NRTI dual therapy),
and July 1996 to June 1999 (period 3: mainly triple combination
therapy). Patients AIDS-free and alive were considered as lost to fol-
low-up in period 1 and period 2 if their last visit occurred in period 1
or 2, respectively. Patients followed in period 3 were considered as lost
to follow-up if they had no hospital visit after June 1998.
Recruitment in our cohort implies that subjects with a shorter incu-
bation time have less chance to enter the database AIDS-free and,
consequently, less chance to be included in the analysis than subjects
with a longer incubation time (9,10). To overcome this survival bias,
patient follow-up was left truncated until the first hospital visit (11,12).
Moreover, a subject contributed to the risk set in each calendar period
he or she was followed while AIDS-free; therefore, we left-truncated
the follow-up at the beginning of each calendar period in which he or
she contributed (13,14).
Nonparametric AIDS-free probabilities in the three periods were
assessed using the Kaplan-Meier method and compared by the Cox
proportional hazards model. The Cox model was adjusted for age at
infection, transmission group (homosexual, intravenous drug user, het-
erosexual, and other), period of seroconversion (1986, 1987–1991,
1992–June 1995, July 1995–June 1996, after July 1996), and calendar
periods, entered as time-dependent covariates.
Parametric estimates of the median incubation time in the three
calendar periods were derived from log-normal distribution, which has
been shown to better suit the time variation in the hazard of AIDS than
a Weibull model (15–17). To overcome the departure from the log-
normal model at the tail of the observed times, which is most relevant
for predictions, left truncation was extended to 5 years after the sero-
conversion as recommended by Muñoz and Xu (16). Log-exponential
and Weibull models were used to assess the robustness of the lognor-
mal model in the third period.
Antiretroviral and Prophylaxis Treatments
For each subject followed in a given period, we examined the treat-
ments prescribed at the last follow-up visit while the patient was still
AIDS-free. Antiretroviral regimens were analyzed according to the
time lag from infection at this visit and classified in three categories
according to the number of drugs used: monotherapy, dual therapy, and
triple therapy. Triple therapy was defined as the concomitant use of
three or more antiretroviral drugs. Pneumocystis carinii prophylaxis
was defined as any use of sulfamethoxazole/trimethoprim, aerosolized
pentamidine, dapsone, or atovaquone.
Statistical analyses were performed using SAS (version 6.12; SAS
Institute, Cary, NC, U.S.A.) and S+ (version 5.0; MathSoft, Seattle,
WA, U.S.A.) computer programs and a C program for estimating
AIDS-free probabilities.
RESULTS
Overall, 4702 subjects fulfilled the inclusion criteria.
Of these, 2962 (63.0%) had a test interval within 24
months. The remaining subjects were documented on the
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contamination (1131 subjects [24.0%]).
In the study sample, 3406 subjects (72.4%) were male,
2257 (48.0%) were homosexual men, 1700 (36.2%) were
heterosexuals, and 509 (10.8%) were intravenous drug
users. For 236 subjects (5.0%), the transmission group
was unknown. The median age at infection was 28.8
years. Overall, 1982 subjects were infected between
1986 and 1991: 1636 during period 1, 387 during period
2, and 697 during period 3.
After infection, the median time before the first hos-
pital visit was 12 months (interquartile range: 5–40
months). The median follow-up interval was 63 months
(5.2 years). From 1992 to June 1999, 862 subjects
(18.3%) developed a first AIDS-defining event, and 67
(1.4%) died while AIDS-free. More patients were lost to
follow-up in period 3 (11.5%) than in period 1 (7.5%) or
period 2 (4%). Overall, patients were lost to follow-up
after a median interval while AIDS-free of 53 months.
Table 1 presents the characteristics of the subjects fol-
lowed during the three calendar periods. Infection dura-
tion before the first hospital visit was similar in the three
calendar periods. The three groups were relatively simi-
lar regarding age at infection, sex, and transmission
group distribution. In all periods, approximately two
thirds of the dates of infection were documented on the
basis of test interval.
Figure 1 shows the Kaplan-Meier estimates of AIDS-
free probabilities in the three calendar periods. The prob-
ability of remaining AIDS-free at 5 years was estimated
as 69.2% in period 1 (95% confidence interval [CI]:
66.1– 72.2), 77.6% in period 2 (CI: 73.3–81.9), and
89.9% in period 3 (CI: 87.9–91.9).
Table 2 presents the results of relative hazard (RH) of
progression to AIDS across the calendar periods in uni-
variate analysis and after adjusting for age at infection,
transmission group, and period of infection. The RH of
progression to AIDS was significantly reduced in period
3 compared with period 2 or period 1 and remained
similar after adjustment. The reduction in the hazard of
AIDS observed between periods 2 and 1 was borderline
significant in the multivariate analysis. Under a lognor-
mal assumption, the median time between HIV-1 infec-
tion and the development of AIDS was estimated to be
8.0 years (CI: 6.0–10.6) in period 1, 9.8 years (CI: 8.5–
11.2) in period 2, and 20.0 years (CI: 17.1–23.3) in pe-
riod 3. In period 3, whether the log-exponential model or
the Weibull model was used, estimates were similar;








Number of patients followed during the period 2684 2540 3732
Total person-years 4829 2109 7817
General characteristics
Median date of infection April 1991 February 1992 June 1993
Date of infection during the period (%) 39.3 5.7 18.7
Median age at infection (years) 28.1 28.0 28.8
Male (%) 72.1 71.1 71.7
Men who have sex with men (%) 48.2 47.5 47.1
Inclusion and date of infection
Last negative and first positive HIV-1 test within 24 months
(%) 66.1 65.4 62.4
Date of first infection only (%) 13.0 12.1 13.0
Date of contamination only (%) 20.9 22.4 24.6
Staggered entries
Number of patients with first visit before the period
a 681 1998 2256
Median infection duration at the beginning of the period and
25% through 75% percentiles (months) 36 (20–54) 46 (27–72) 51 (30–77)
Number of patients with first visit during the period
b 2003 542 1476
Median infection duration at first visit and 25% through
75% percentiles (months) 13 (6–42) 14 (6–42) 12 (5–47)
Follow-up from infection to the end of the period
Median duration and 25% through 75% percentiles (months) 46 (26–71) 51 (30–77) 67 (38–97)
Number of AIDS cases (%) 453 (16.9) 171 (6.7) 238 (6.4)
Number of deaths before an AIDS diagnosis (%) 32 (1.2) 11 (0.4) 24 (0.6)
Number lost to follow-up (%)
c 201 (7.5) 102 (4.0) 431 (11.5)
a Left truncation at the beginning of the period.
b Left truncation at the first hospital visit.
c Subjects AIDS-free at the last hospital visit occurring during the period or before July 1998 for the third period.
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17.6–22.3), respectively.
Whatever the infection duration, the proportion of sub-
jects receiving antiretroviral treatment strikingly in-
creased over the three periods, and the nature of regi-
mens changed (Fig. 2). The increase in antiretroviral
prescriptions was particularly marked for the persons re-
cently infected. In period 1, 16.4% of the subjects in-
fected for less than 1 year were treated versus 29.2% in
period 2 and 54.5% in period 3. Overall, 34.4% of the
subjects were treated in period 1 compared with 47.1% in
period 2 and 75.5% in period 3. Treatments prescribed
were monotherapy for 74.4% of subjects treated in pe-
riod 1, dual therapy for 73.4% of subjects treated in
period 2, and triple therapy for 70.7% of subjects treated
in period 3.
In period 1, 23.0% of the subjects received P. carinii
prophylaxis versus 21.0% in period 2 and 14.2% in pe-
riod 3.
DISCUSSION
Our study of the quantitative changes of time to AIDS
after infection across successive periods revealed a major
lengthening of AIDS-free times concomitant with the
introduction of triple therapy for HIV in the late 1990s.
Parametric and nonparametric estimates provided evi-
dence of a reduction in the progression to AIDS across







Period 2 versus period 1 7/1/95–6/30/96 versus 1/1/92–6/30/95 0.79 0.66–0.94 0.78 0.65–0.94 0.86 0.71–1.05
Period 3 versus period 1 7/1/96–6/30/99 versus 1/1/92–6/30/95 0.27 0.22–0.32 0.26 0.22–0.31 0.31 0.24–0.39
Period 3 versus period 2 7/1/96–6/30/99 versus 7/1/95–6/30/96 0.34 0.28–0.42 0.33 0.27–0.41 0.36 0.29–0.45
a Adjusted for age at infection and transmission group.
b Adjusted for age at infection, transmission group, and period of infection.
RH, relative hazard; CI, 95% confidence interval.
FIG 1. Kaplan-Meier estimates of AIDS-free survival in the three calendar periods of follow-up.
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most recent period. The probability of remaining AIDS-
free 5 years after infection increased from 69.2% before
mid-1995, to 77.6% between mid-1995 and mid-1996, to
89.9% after mid-1996. Similarly, we observed a 64%
reduction in the hazard of AIDS after mid-1996 com-
pared with the previous period. The hazard of AIDS
between the periods after and before mid-1995 was also
reduced but not significantly. The median time to AIDS
was estimated as 8.0 years before mid-1995, 9.8 years
from mid-1995 to mid-1996, and 20.0 years from mid-
1997 to mid-1999.
Our results are consistent with those previously pub-
lished in seroconverter cohort studies with known dura-
tion of infection. For the Multicenter AIDS Cohort
Study, Detels et al. (7) compared subjects with the same
infection duration in four calendar periods with different
regimen availability. This study demonstrated a reduc-
tion in the hazard of AIDS or death in the latest period
after introduction of potent antiretroviral therapy com-
pared with the period when only monotherapy was avail-
able (AIDS RH  0.35). In the Italian HIV Seroconver-
sion Study, the RH of death and the RH of AIDS-related
death were both estimated to be 0.54 in 1997 compared
with before 1991 (5). A pooled analysis of 38 studies
concluded that there was a significant survival benefit 10
years after infection in the period from 1997 to 1998
compared with before 1997 (6). Our results are also con-
sistent with results estimated in prevalence cohorts by
comparing progression since a defined level of prognos-
tic markers instead of the date of infection (18).
Several biases and potential confounding factors that
could interfere with the results should be discussed. First,
to address a potential survival bias, time duration was
restricted for each patient to the period of active follow-
up since the first hospital visit.
Second, among factors known to influence AIDS in-
cubation time, age at infection is the most often reported
(19–21) and was introduced in the multivariate analyses,
and it did not modify the estimates. This can be ex-
plained by a similar median age at infection for patients
in the three periods. Host genetic factors (22,23) have
also been reported to influence the progression to
AIDS, but it is rather unlikely that these genetic charac-
teristics of HIV-infected patients have changed over
time. In contrast, one can imagine that changes in viral
FIG. 2. Antiretroviral regimen at patients’ last follow-up visit while AIDS-free in each period according to the duration of incubation at this
visit.
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for periods of seroconversion did not affect the results,
however.
Third, it has been reported that when Kaposi sarcoma,
a tumor almost exclusively diagnosed in homosexual
men, is not excluded from the AIDS definition, the risk
of progression to AIDS is higher in homosexual men
than for other transmission groups (24). This was ac-
counted for in the analysis by adjusting for transmission
groups, and, again, the results did not vary.
Fourth, in the literature, the date of HIV infection is
most often documented on the basis of a test interval
(5,7,24). In our study, test intervals were not available
for one third of the patients, and only the dates of pri-
mary infection or contamination were. Nevertheless, a
sensitivity analysis restricted to subjects with a date of
infection documented on the basis of a test interval (n 
2692) showed similar risk of progression to AIDS (data
not shown).
Finally, concern could be raised about a possible bias
caused by an informative censoring of the 11.5% of pa-
tients followed in the last period who were lost to follow-
up. We performed a sensitivity analysis assuming that
these patients had a diagnosis of AIDS the day after their
last visit. The RH of AIDS remained significantly re-
duced in period 3 compared with period 1 (RH  0.88;
CI: 0.77–0.99).
Thus, none of the factors discussed previously could
really explain the lengthening in time to AIDS that we
observed. The fact remains that over the three periods,
the most striking difference was the change in the use of
antiretroviral regimens. Antiretroviral treatments were
initiated earlier after infection and with more potent regi-
mens (see Fig. 2). It is therefore likely that the length-
ening in time to AIDS should be attributed to the intro-
duction of NRTI combinations and that it has been
greatly marked since the introduction of triple therapy,
including protease inhibitors. By providing quantitative
estimates of the impact of antiretroviral combination
therapy, including protease inhibitors, at the population
level, our results complement the efficacy results of an-
tiretroviral combination demonstrated in clinical trials in
advanced patients and the effectiveness described in ob-
servational studies (25–27).
In conclusion, we observed a lengthening in time to
AIDS from 1992 to 1999, which was particularly marked
in the most recent period. Although this improvement
may reflect differences in calendar periods, it is most
likely related to the change in antiretroviral regimen
management over time and the introduction of triple
therapy, including protease inhibitors.
Acknowledgments: The French Hospital Database on HIV
is supported by the Agence Nationale de Recherches sur le
SIDA, Fondation pour la Recherche Médicale, Institut National
de la Santé et de la Recherche Médicale, and French Ministry
of Health.
APPENDIX
Clinical Epidemiology Group of the French
Hospital Database on HIV
• Scientific Committee: S. Alfandari, F. Bastides, E. Billaud, A. Boi-
bieux, F. Boué, F. Bricaire, D. Costagliola, L. Cotte, L. Cuzin, F.
Dabis, S. Fournier, J. Gasnault, C. Gaud, J. Gilquin, S. Grabar, D.
Lacoste, J.M. Lang, H. Laurichesse, C. Leport, M. Mary-Krause, S.
Matheron, M.C. Meyohas, C. Michelet, J. Moreau, G. Pialoux, I.
Poizot-Martin, C. Pradier, C. Rabaud, E. Rouveix, P. Saïag, D.
Salmon-Ceron, J. Soubeyrand, and H. Tissot-Dupont.
• DMI2 Coordinating Center, French Ministry of Health: B. Haury, V.
Tirard-Fleury, S. Courtial-Destembert, G. Leblanc, and C. Mahdavi.
• Statistical Data Analysis Center, Institut National de la Santé et de la
Recherche Médicale SC4: S. Abgrall, S. Benoliel, D. Costagliola, S.
Grabar, L. Lièvre, and M. Mary-Krause.
• Centres d’Information et de Soins de l’Immunodéficience Humaine
(CISIH)
• Paris area: CISIH de Bichat-Claude Bernard (Hôpital Bichat-Claude
Bernard: S. Matheron, J.P. Coulaud, J.L. Vildé, C. Leport, P. Yeni,
E. Bouvet, C. Gaudebout, B. Crickx, and C. Picard-Dahan), CISIH
de Paris-Centre (Hôpital Broussais: L. Weiss and D. Aureillard; GH
Tarnier-Cochin: D. Sicard and D. Salmon; Hôpital Saint-Joseph: J.
Gilquin and I. Auperin), CISIH de Paris-Ouest (Hôpital Necker adul-
tes: J.P. Viard; Hôpital Laennec: W. Lowenstein; Hôpital de
l’Institut Pasteur), CISIH de Paris-Sud (Hôpital Antoine Béclère: F.
Boué and R. Fior; Hôpital de Bicêtre: C. Goujard and C. Rousseau;
Hôpital Henri Mondor; Hôpital Paul Brousse), CISIH de Paris-Est
(Hôpital Rothschild: W. Rozenbaum and C. Maslo; Hôpital Saint-
Antoine: M.C. Meyohas, J.L. Meynard, O. Picard, and N. Des-
planque; Hôpital Tenon: J. Cadranel and C. Mayaud), CISIH de
Pitié-Salpétrière (GH Pitié-Salpétrière: F. Bricaire and C. Katlama),
CISIH de Saint-Louis (Hôpital Saint-Louis: J.M. Decazes, J.M. Mo-
lina, and L. Gerard; GH Lariboisière-Fernand Widal: J.M. Salord and
D. Diermer), CISIH 92 (Hôpital Ambroise Paré: C. Dupont, H. Ber-
thé, and P. Saïag; Hôpital Louis Mourier: C. Michon and C. Chan-
demerle; Hôpital Raymond Poincaré: P. de Truchis), and CISIH 93
(Hôpital Avicenne: M. Bentata and P. Berlureau; Hôpital Jean
Verdier: J. Franchi and V. Jeantils; Hôpital Delafontaine: D. Mechali
and B. Taverne).
• Outside Paris area: CISIH Auvergne-Loire (Centre Hospitalier Uni-
versitaire [CHU] de Clermont-Ferrand: H. Laurichesse and F. Gour-
don; Centre Hospitalier Re ´gional Universitaire [CHRU] de Saint-
Etienne: F. Lucht and A. Fresard); CISIH de Bourgogne-Franche
Comté CHRU de Besançon; CHRU de Dijon; CH de Belfort: J.P.
Faller and P. Eglinger); CISIH de Caen (CHRU de Caen: C. Bazin
and R. Verdon); CISIH de Grenoble (CHU de Grenoble); CISIH de
Lyon (Hôpital de la Croix-Rousse; Hôpital Edouard Herriot: J.L.
Touraine and T. Saint-Marc; Hôtel-Dieu; Centre Hospitalier (CH) de
Lyon-Sud: Médecine Pénitentiaire), CISIH de Marseille (Hôpital de
la Conception: I. Ravaux and H. Tissot-Dupont; Hôpital Houphouët-
Boigny: J. Moreau; Institut Paoli Calmettes; Hôpital Sainte-
Marguerite: J.A. Gastaut, I. Poizot-Martin, J. Soubeyrand, and F.
Retornaz; Hotel-Dieu; CHG d’Aix-En-Provence; Centre pénitenti-
J.-M. TASSIE ET AL. 86
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 30, No. 1, May 1, 2002aire des Baumettes; CH d’Arles; CH d’Avignon: G. Lepeu; CH de
Digne Les Bains: P. Granet-Brunello; CH de Gap: L. Pelissier and
J.P. Esterni; CH de Martigues: M. Nezri and Y. Ruer; CHI de Tou-
lon), CISIH de Montpellier (CHU de Montpellier: J. Reynes; CHG
de Nîmes), CISIH de Nancy (Hôpital de Brabois: T. May and C.
Rabaud), CISIH de Nantes (CHRU de Nantes: F. Raffi and M.F.
Charonnat), CISIH de Nice (Hôpital Archet 1: C. Pradier and P.
Pugliese; CHG Antibes Juan les Pins), CISIH de Rennes (CHU de
Rennes: C. Michelet and C. Arvieux), CISIH de Rouen (CHRU de
Rouen: F. Caron and Y. Debas), CISIH de Strasbourg (CHRU de
Strasbourg: J.M. Lang, D. Rey, and P. Fraisse; CH de Mulhouse),
CISIH de Toulouse (CHU Purpan: M. Perez, F. Balsarin, E. Arlet-
Suau, and M.F. Thiercelin Legrand; Hôpital la Grave; CHU
Rangueil), CISIH de Tourcoing-Lille (CH Gustave Dron; CH de
Tourcoing: S. Alfandari and Y. Yasdanpanah), and CISIH de Tours
(CHRU de Tours; CHU Trousseau).
• Overseas: CISIH de Guadeloupe (CHRU de Pointe-à-Pitre), CISIH
de Guyane (CHG de Cayenne: M. Sobesky and R. Pradinaud),
CISIH de Martinique (CHRU de Fort-de-France), and CISIH de La
Réunion (CHD Félix Guyon: C. Gaud and M. Contant).
REFERENCES
1. Muñoz A, Gange SJ, Jacobson LP. Distinguishing efficacy, indi-
vidual effectiveness and population effectiveness of therapies.
AIDS 2000;14:754–6.
2. Brookmeyer R, Liao JG. Statistical modeling of the AIDS epi-
demic for forecasting health care needs. Biometrics 1990;46:
1151–63.
3. Taylor JM, Kuo JM, Detels R. Is the incubation period of AIDS
lengthening? J Acquir Immune Defic Syndr Hum Retrovirol 1991;
4:69–75.
4. Cozzi Lepri A, Sabin CA, Phillips AN. Investigating temporal
changes in the rate of HIV progression: challenges and limitations.
AIDS 1997;11:1647–9.
5. Dorrucci M, Balducci M, Pezzotti P, et al. Temporal changes in the
rate of progression to death among Italians with known date of
HIV seroconversion: estimates of the population effect of treat-
ment. Italian HIV Seroconversion Study. J Acquir Immune Defic
Syndr 1999;22:65–70.
6. The CASCADE Collaboration. Survival after introduction of
HAART in people with known duration of HIV-1 infection. Con-
certed action on seroconversion to AIDS and death in Europe
[letter]. Lancet 2000;355:1158–9.
7. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent
antiretroviral therapy on time to AIDS and death in men with
known HIV infection duration. JAMA 1998;280:1497–503.
8. Tassie JM, Gasnault J, Bentata M, et al. Survival improvement of
AIDS-related progressive multifocal leukoencephalopathy in the
era of protease inhibitors. AIDS 1999;13:1881–7.
9. Muñoz A, Sabin CA, Phillips AN. The incubation period of AIDS.
AIDS 1997;11(Suppl):S69–76.
10. Brookmeyer R, Gail MH, Polk BF. The prevalent cohort study and
the acquired immunodeficiency syndrome. Am J Epidemiol 1987;
126:14–24.
11. UK Register of HIV Seroconverters Steering Committee. The
AIDS incubation period in the UK estimated from a national reg-
ister of HIV seroconverters. AIDS 1998;12:659–67.
12. Hessol NA, Koblin BA, van Griensven GJ, et al. Progression of
human immunodeficiency virus type 1 (HIV-1) infection among
homosexual men in hepatitis B vaccine trial cohorts in Amsterdam,
New York City, and San Francisco, 1978–1991. Am J Epidemiol
1994;139:1077–87.
13. Muñoz A, Hoover DR. Use of cohort studies for evaluating AIDS
therapies. In Finkelstein DM, ed. AIDS clinical trials. New York:
John Wiley & Sons, 1995:423–46.
14. Tsai WY, Jewell NP, Wang MC. A note on the product-limit
estimator under right censoring and left truncation. Biometrika
1987;74:883–6.
15. Melbye M, Begtrup K, Rosenberg PS, et al. Differences in sus-
ceptibility to AIDS development: a cohort study of Danish and
American homosexual-bisexual men, 1981 to 1995. J Acquir Im-
mune Defic Syndr Hum Retrovirol 1998;18:270–6.
16. Muñoz A, Xu J. Models for the incubation of AIDS and variations
according to age and period. Stat Med 1996;15:2459–73.
17. Veugelers PJ, Cornelisse PG, Craib KJ, et al. Models of survival in
HIV infection and their use in the quantification of treatment ben-
efits. Am J Epidemiol 1998;148:487–96.
18. Tarwater PM, Mellors J, Gore ME, et al. Methods to assess popu-
lation effectiveness of therapies in human immunodeficiency virus
incident and prevalent cohorts. Am J Epidemiol 2001;154:675–81.
19. Alioum A, Leroy V, Commenges D, et al. Effect of gender, age,
transmission category, and antiretroviral therapy on the progres-
sion of human immunodeficiency virus infection using multistate
Markov models. Epidemiology 1998;9:605–12.
20. Pezzotti P, Phillips AN, Dorrucci M, et al. Category of exposure to
HIV and age in the progression to AIDS: longitudinal study of
1199 people with known dates of seroconversion. BMJ 1996;313:
583–6.
21. Phillips AN, Lee CA, Elford J, et al. More rapid progression to
AIDS in older HIV-infected people: the role of CD4
+ T-cell
counts. J Acquir Immune Defic Syndr Hum Retrovirol 1991;4:
970–5.
22. Dean M, Carrington M, Winkler C, et al. Genetic restriction of
HIV-1 infection and progression to AIDS by a deletion allele of the
CKR5 structural gene. Science 1996;273:1856–62.
23. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of
AIDS progression by a promoter variant of CCR5. Science 1998;
282:1907–11.
24. Collaborative Group on AIDS Incubation and HIV Survival In-
cluding the CASCADE EU Concerted Action. Concerted action on
seroconversion to AIDS and Death in Europe. Time from HIV-1
seroconversion to AIDS and death before widespread use of highly
active antiretroviral therapy: a collaborative reanalysis. Lancet
2000;355:1131–7.
25. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of
two nucleoside analogues plus indinavir in persons with human
immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. NE n g lJM e d1997;337:725–33.
26. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretro-
viral combination therapies in HIV infected patients in Switzer-
land: prospective multicentre study. Swiss HIV Cohort Study. BMJ
1997;315:1194–9.
27. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mor-
tality across Europe in patients infected with HIV-1. EuroSIDA
Study Group. Lancet 1998;352:1725–30.
TIME TO AIDS IN HIV-1–INFECTED SUBJECTS 87
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 30, No. 1, May 1, 2002